Is Fresenius a good stock to buy?
Fresenius still has extremely high debt levels on its balance sheet and is facing headwinds due to COVID-19 again. But the stock is trading for such low valuation multiples that Fresenius seems like a good investment despite the above-mentioned issues.
Why is Fresenius stock down?
Fresenius Medical Care stock falls ~4% amid JPMorgan downgrade on COVID impact. Fresenius Medical Care (FMS -3.7%) was downgraded by JPMorgan to Underweight from Neutral with a EUR 60.80 price target. The analyst expects a "near-term squeeze" on the company's revenues and costs from accelerating Covid-19 deaths.
Is Fresenius publicly traded?
Fresenius Medical Care, a publicly traded company of which Fresenius owns 30.8%, focuses on patients with chronic kidney failure. With a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States.
Who owns Fresenius?
The company is 32% owned by Fresenius and, as of 2020, generates around 50% of the group's revenue....Fresenius Medical Care.TypeKGaA with Aktiengesellschaft as partner with unlimited liabilityRevenue€17.62 billion (2021)Operating income€1,852 million (2021)Net income€969 million (2021)Total assets€34,367 million (2021)13 more rows
What is Fresenius net worth?
Fresenius SE net worth as of June 24, 2022 is $16.2B. Fresenius SE & Co is a health care company.
Is Fresenius a for profit company?
3 answers. Yes they are a company that is not for profit.
Is Fresenius Medical Care for sale?
Fresenius Medical Care completes sale of clinics as part of Liberty Dialysis acquisition.
Is DaVita or Fresenius bigger?
DaVita maintains over 2,800 brick-and-mortar dialysis centers in the U.S., while Fresenius' North America subsidiary owns more than 2,500 on the continent—together accounting for more than 80% of the entire U.S. market.
Is Fresenius better than DaVita?
DaVita is most highly rated for Culture and Fresenius Medical Care is most highly rated for Compensation and benefits....Overall Rating.Overall Rating3.33.4Culture3.23.14 more rows
Is Fresenius a Fortune 500?
A partnership. What do you think of Fresenius? U.S....Our annual ranking of the world's largest corporations.$ millions% change from 2010Revenues22,973.08.6Profits959.416.5Assets34,172.5--1 more row
Key Catalysts
Fresenius Medical provides access a wide range of Dialysis products in its own dialysis clinics and third-party clinics. These include modular machine components, dialyzers, bloodline systems, HD (hemodialysis) solutions, concentrates and water treatment systems.
Which Way are Estimates Headed?
For 2020, the Zacks Consensus Estimate for revenues is pegged at $21.46 billion, indicating an improvement of 9.7% from the prior-year quarter. The same for adjusted earnings per share stands at $2.61, suggesting growth of 3.2% from the year-ago reported figure.
Other Stocks to Consider
Some other top-ranked stocks from the broader medical space include West Pharmaceutical Services, Inc. ( WST Quick Quote WST - Free Report) , Thermo Fisher Scientific Inc. ( TMO Quick Quote TMO - Free Report) and PerkinElmer, Inc. ( PKI Quick Quote PKI - Free Report) .
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Fresenius Medical Care AG & Co. (FMS)
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Style Scorecard
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
Chart for FMS
Based in Bad Homburg, Germany, Fresenius Medical Care AG & Co. KGaA (FMS) is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Formed in 1996 following the merger of the dialysis business of Fresenius AG and the U. S.
Signals & Forecast
The Fresenius Medical Care Corporation stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Support, Risk & Stop-loss
Fresenius Medical Care Corporation finds support from accumulated volume at $32.43 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Fresenius Medical Care Corporation stock A Buy?
Fresenius Medical Care Corporation holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Fresenius Medical Care Corporation
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis treatment and related dialysis care services, and other health care services.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What is Fresenius Medical Care?
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
What is the FMS symbol?
Fresenius Medical Care AG & Co. KGaA trades on the New York Stock Exchange (NYSE) under the ticker symbol "FMS."
How much will biotech industry grow in 2024?
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Is Fresenius a value investor?
Fresenius Medical Care is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (bottom 34% out of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past one year, the sector has clearly underperformed the broader market, as you can see below:
What is the ticker symbol for Fresenius?
Fresenius SE & Co. KGaA trades on the OTCMKTS under the ticker symbol "FSNUY."
What is Fresenius SE?
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Corporate and Other. The Fresenius Medical Care segment comprises of dialysis products and healthcare services. The Fresenius Kabi segment specializes in intravenous drugs, clinical nutrition, infusion therapy, medical devices, and transfusion technology. The Fresenius Helios focuses on the private hospital operations. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The Corporate and Other segment includes the holding activities. The company was founded by Eduard Fresenius in October 1912 and is headquartered in Bad Homburg, Germany.
What is the P/E ratio of Fresenius SE?
The P/E ratio of Fresenius SE & Co. KGaA is 10.24 , which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.42.
Does Fresenius have a long track record?
Fresenius SE & Co. KGaA does not have a long track record of dividend growth.
Key Catalysts
- Fresenius Medical provides access a wide range of Dialysis products in its own dialysis clinics and third-party clinics. These include modular machine components, dialyzers, bloodline systems, HD (hemodialysis) solutions, concentrates and water treatment systems. At year-end 2019, home dialysis accounted for 13% of all treatments in the United Stat...
Which Way Are Estimates Headed?
- For 2020, the Zacks Consensus Estimate for revenues is pegged at $21.46 billion, indicating an improvement of 9.7% from the prior-year quarter. The same for adjusted earnings per share stands at $2.61, suggesting growth of 3.2% from the year-ago reported figure.
Other Stocks to Consider
- Some other top-ranked stocks from the broader medical space include West Pharmaceutical Services, Inc. (WST - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and PerkinElmer, Inc. (PKI - Free Report) . While PerkinElmer sports a Zacks Rank of 1, both Thermo Fisher and West Pharmaceuticals carry a Zacks Rank #2. You can see the complete list of today’…
The Hottest Tech Mega-Trend of All
- Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >>